We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04913337
Recruitment Status : Recruiting
First Posted : June 4, 2021
Last Update Posted : September 15, 2022
Sponsor:
Collaborator:
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
NGM Biopharmaceuticals, Inc

Tracking Information
First Submitted Date  ICMJE May 20, 2021
First Posted Date  ICMJE June 4, 2021
Last Update Posted Date September 15, 2022
Actual Study Start Date  ICMJE June 9, 2021
Estimated Primary Completion Date February 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: September 22, 2021)
  • Number of Patients with Dose-limiting Toxicities [ Time Frame: Baseline up to 28 Days ]
    A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0, and is considered by the investigator to be clinically relevant and attributed to the study treatment during the first 28 days after the first dose of study treatment.
  • Incidence of Adverse Events [ Time Frame: Baseline up to Approximately 24 Months ]
    Number of patients with adverse events (AEs) according to severity, seriousness, and relationship to study drug An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of patients who experience at least one AE will be presented.
  • Number of Patients with Clinically Significant Laboratory Abnormalities [ Time Frame: Baseline up to Approximately 24 Months ]
    Number of patients with clinically significant change from baseline in laboratory abnormalities as characterized by type, frequency, severity (graded by CTCAE version 5.0) and timing.
  • Number of Patients in Expansion Cohorts with Objective Responses [ Time Frame: Baseline up to approximately 24 months ]
    Objective Response Rate is defined as the proportion of patients who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1
  • Duration of Response for Patients in Expansion Cohorts [ Time Frame: Baseline up to approximately 24 months ]
    Duration of Response is defined as the time from the first documentation of objective response (CR or PR) that is subsequently confirmed per RECIST v1.1, to the time of the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.
  • Progression-free Survival for Patients in Expansion Cohorts [ Time Frame: Baseline up to approximately 24 months ]
    Progression-free survival is defined as the time from start of study treatment to the date of first documentation of objective tumor progression on or following study therapy per RECIST v1.1, or to death due to any cause, whichever comes first.
  • Overall Survival for Patients in Combination Dose Expansion Cohorts [ Time Frame: Up to approximately 48 months ]
    Overall survival is defined as the date from start of the study treatment to the date of death due to any cause.
Original Primary Outcome Measures  ICMJE
 (submitted: June 2, 2021)
  • Number of Patients with Dose-limiting Toxicities [ Time Frame: Baseline up to 28 Days ]
    A DLT is defined as an AE that meets at least one of the criteria listed in protocol, according to National Cancer Institute (NCI) common terminology criteria for AE (CTCAE) version 5.0, and is considered by the investigator to be clinically relevant and attributed to the study treatment during the first 28 days after the first dose of study treatment.
  • Incidence of Adverse Events [ Time Frame: Baseline up to Approximately 24 Months ]
    Number of patients with adverse events (AEs) according to severity, seriousness, and relationship to study drug An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of patients who experience at least one AE will be presented.
  • Number of Patients with Clinically Significant Laboratory Abnormalities [ Time Frame: Baseline up to Approximately 24 Months ]
    Number of patients with clinically significant change from baseline in laboratory abnormalities as characterized by type, frequency, severity (graded by CTCAE version 5.0) and timing.
  • Number of Patients in Expansion Cohorts with Objective Responses [ Time Frame: Baseline up to approximately 24 months ]
    Objective Response Rate is defined as the proportion of patients who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1
  • Duration of Response for Patients in Expansion Cohorts [ Time Frame: Baseline up to approximately 24 months ]
    Duration of Response is defined as the time from the first documentation of objective response (CR or PR) that is subsequently confirmed per RECIST v1.1, to the time of the first documentation of objective tumor progression or to death due to any cause, whichever occurs first.
  • Progression-free Survival for Patients in Expansion Cohorts [ Time Frame: Baseline up to approximately 24 months ]
    Progression-free survival is defined as the time from start of study treatment to the date of first documentation of objective tumor progression on or following study therapy per RECIST v1.1, or to death due to any cause, whichever comes first.
  • Overall Survival for Patients in Expansion Cohorts of Part 2b [ Time Frame: Up to approximately 48 months ]
    Overall survival is defined as the date from start of the study treatment to the date of death due to any cause.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: September 22, 2021)
  • Observed Plasma Concentration of NGM707 (Including Cmax) [ Time Frame: Baseline up to approximately 24 months ]
    Will be measured on Day 1, 2, 4, 8 and 15 of Cycles 1 and 3, Day 1 of Cycle 2 and Day 1 of Cycle 4 and each cycle thereafter.
  • Area Under the Curve (AUC) of Plasma NGM707 [ Time Frame: Baseline up to approximately 24 months ]
    Area under the curve from time zero extrapolated to the last quantifiable dose of NGM707. Time zero extrapolated to the last quantifiable time point prior to the next dose. Will be measured on Day 1, 2, 4, 8 and 15 of Cycles 1 and 3, Day 1 of Cycle 2 and Day 1 of Cycle 4 and each cycle thereafter.
  • Plasma Half-life (t1/2) of NGM707 [ Time Frame: Baseline up to approximately 24 months ]
    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Will be measured on Day 1, 2, 4, 8 and 15 of Cycles 1 and 3, Day 1 of Cycle 2 and Day 1 of Cycle 4 and each cycle thereafter.
  • Anti-drug Antibodies (ADA) Against NGM707 [ Time Frame: Baseline up to approximately 24 months ]
    Incidence and titers of anti-drug antibodies (ADA) against NGM707. Will be measured on Day 1 of each cycle.
Original Secondary Outcome Measures  ICMJE
 (submitted: June 2, 2021)
  • Observed Plasma Concentration of NGM707 (Including Cmax) [ Time Frame: Baseline up to approximately 24 months ]
    NGM707 will be measured at the end of infusion on Cycle 1 Day 1 and on days 2, 4, 8, and 15 of Cycle 1; pre-dose and end of infusion on Day 1 of Cycle 2, and every cycle thereafter.
  • Area Under the Curve (AUC) of Plasma NGM707 [ Time Frame: Baseline up to approximately 24 months ]
    Area under the curve from time zero extrapolated to the last quantifiable dose of NGM707. Time zero extrapolated to the last quantifiable time point prior to the next dose. NGM707 will be measured at the end of infusion on Cycle 1 Day 1 and on days 2, 4, 8, and 15 of Cycle 1; pre-dose and end of infusion on Day 1 of Cycle 2, and every cycle thereafter.
  • Plasma Half-life (t1/2) of NGM707 [ Time Frame: Baseline up to approximately 24 months ]
    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. NGM707 will be measured at the end of infusion on Cycle 1 Day 1 and on days 2, 4, 8, and 15 of Cycle 1; pre-dose and end of infusion on Day 1 of Cycle 2, and every cycle thereafter.
  • Anti-drug Antibodies (ADA) Against NGM707 [ Time Frame: Baseline up to approximately 24 months ]
    Incidence and titers of anti-drug antibodies (ADA) against NGM707. NGM707 will be measured pre-dose on Day 1 of Cycle 1, and every cycle thereafter.
  • Neutralizing Antibodies (NAb) Against NGM707 [ Time Frame: Baseline up to approximately 24 months ]
    Incidence and titers of neutralizing antibodies (NAb) against NGM707. NGM707 will be measured pre-dose on Day 1 of Cycle 1, and every cycle thereafter.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Official Title  ICMJE A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Brief Summary Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Mesothelioma
  • Glioblastoma
  • Renal Cell Carcinoma
  • Non Small Cell Lung Cancer
  • Melanoma
  • Pancreatic Ductal Adenocarcinoma
  • Gastric Cancer
  • Squamous Cell Carcinoma of Head and Neck
  • Cholangiocarcinoma
  • Breast Cancer
  • Ovarian Cancer
  • Cervical Cancer
  • Endocervical Cancer
  • Colorectal Cancer
  • Esophageal Cancer
Intervention  ICMJE
  • Drug: NGM707

    Drug: NGM707

    NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.

  • Drug: NGM707 plus pembrolizumab

    Drug: NGM707

    NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.

    Drug: pembrolizumab

    Pembrolizumab will be administered intravenously (IV) every 3 weeks in a 21 day cycle.

  • Drug: NGM707

    Drug: NGM707

    Preliminary recommended phase 2 dose (RP2D) of NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle.

  • Drug: NGM707 plus pembrolizumab

    Drug: NGM707

    Preliminary recommended phase 2 dose (RP2D) of NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle.

    Drug: pembrolizumab

    Pembrolizumab will be administered intravenously (IV) every 3 weeks in a 21 day cycle.

Study Arms  ICMJE
  • Experimental: NGM707 Monotherapy Dose Escalation
    Part 1a Single Agent Dose Escalation
    Intervention: Drug: NGM707
  • Experimental: NGM707 Combination Dose Finding with pembrolizumab
    Part 1b NGM707 plus pembrolizumab
    Intervention: Drug: NGM707 plus pembrolizumab
  • Experimental: NGM707 Monotherapy Dose Expansion Arm A
    NGM707 in RCC
    Intervention: Drug: NGM707
  • Experimental: NGM707 Monotherapy Dose Expansion Arm B
    NGM707 in CRC
    Intervention: Drug: NGM707
  • Experimental: NGM707 Monotherapy Dose Expansion Arm C
    NGM707 in Ovarian Cancer
    Intervention: Drug: NGM707
  • Experimental: NGM707 Combination Dose Expansion Arm E
    NGM707 with pembrolizumab in NSCLC
    Intervention: Drug: NGM707 plus pembrolizumab
  • Experimental: NGM707 Combination Dose Expansion Arm F
    NGM707 with pembrolizumab in SCCHN
    Intervention: Drug: NGM707 plus pembrolizumab
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: June 2, 2021)
179
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 2025
Estimated Primary Completion Date February 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Histologically or cytologically documented locally advanced or metastatic solid tumor malignancy.
  • Progressed or was intolerant to all available therapies known to confer clinical benefit appropriate for their tumor type, and for which the patient was eligible and willing to receive, or refused SOC treatments that are perceived to have marginal clinical benefit.
  • Adequate bone marrow, kidney and liver function.
  • Performance status of 0 or 1.
  • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1 except for AEs not constituting a safety risk by Investigator judgement.

Exclusion Criteria:

  • Prior treatment targeting ILT2 and/or ILT4 or targeting HLA-G.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: NGM Medical Director (650) 243-5555 NGM707@ngmbio.com
Listed Location Countries  ICMJE Korea, Republic of,   Taiwan,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04913337
Other Study ID Numbers  ICMJE 707-IO-101
KEYNOTE-D25 ( Other Identifier: Merck Sharp & Dohme Corp )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Current Responsible Party NGM Biopharmaceuticals, Inc
Original Responsible Party Same as current
Current Study Sponsor  ICMJE NGM Biopharmaceuticals, Inc
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Merck Sharp & Dohme LLC
Investigators  ICMJE Not Provided
PRS Account NGM Biopharmaceuticals, Inc
Verification Date August 2022

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP